New hope for kids with tough cancers: early safety trial tests adult drug in children
NCT ID NCT02512926
Summary
This early-phase study tested the safety of adding a drug called carfilzomib to two standard chemotherapy drugs (cyclophosphamide and etoposide) for children and young adults whose solid tumors or leukemias had returned or stopped responding to treatment. The main goal was to find the highest dose of this combination that could be given safely without causing severe side effects. Researchers enrolled a small number of participants to carefully monitor how their bodies handled the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alberta Children's Hospital
Calgary, Alberta, T3B 6A8, Canada
-
Arkansas Children's Hospital
Little Rock, Arkansas, 72202, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
Penn State Hershey Children's Hospital
Hershey, Pennsylvania, 17033-0850, United States
-
Phoenix Children's Hospital
Phoenix, Arizona, 85016, United States
-
Stanford University School of Medicine and Stanford Cancer Institute
Palo Alto, California, 94304, United States
-
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.